The biotech announced this morning that it will use its expertise in developing disease models using induced pluripotent stem cells to pursue two new antibody programs targeting the Tau protein and the Complement pathway, routes that could lead to new therapies for Alzheimer's and other neurodegenerative ailments.
Kleiner Perkins Caulfield & Byers has closed the books on a new $525 million fund. And a chunk of that treasure is earmarked for early-stage life science companies.
As a startup, iPierian boasted some of the world's top experts on stem cells. The impeccable scientific pedigree, however, never translated into the kind of partnering deals the biotech was looking
Xconomy's Luke Timmerman has learned the board of hot stem cell start-up iPierian has dismissed much of its senior staff, including CEO Michael Venuti and "executives in charge of finance, business
In a single stroke iPierian has struck a deal to pool its IP on induced pluripotent stem cell technology with Kyoto University and signed on one of the most recognizable names in the field to its
Anyone who has experience in drug development knows how unreliable preclinical animal studies can be. After a therapy has pushed on into Phase II and Phase III, investigators commonly stumble across